FR2337712B1 - - Google Patents

Info

Publication number
FR2337712B1
FR2337712B1 FR7700428A FR7700428A FR2337712B1 FR 2337712 B1 FR2337712 B1 FR 2337712B1 FR 7700428 A FR7700428 A FR 7700428A FR 7700428 A FR7700428 A FR 7700428A FR 2337712 B1 FR2337712 B1 FR 2337712B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7700428A
Other versions
FR2337712A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FR2337712A1 publication Critical patent/FR2337712A1/fr
Application granted granted Critical
Publication of FR2337712B1 publication Critical patent/FR2337712B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C07F9/4059—Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5407—Acyclic saturated phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR7700428A 1976-01-08 1977-01-07 Analogues nouveaux de prostaglandines Granted FR2337712A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/647,357 US4055602A (en) 1976-01-08 1976-01-08 2-Decarboxy-2-hydroxy-methyl-5-oxa-17-phenyl-18,19,20-trinor-PGF-analogs

Publications (2)

Publication Number Publication Date
FR2337712A1 FR2337712A1 (fr) 1977-08-05
FR2337712B1 true FR2337712B1 (fr) 1983-05-20

Family

ID=24596656

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7700428A Granted FR2337712A1 (fr) 1976-01-08 1977-01-07 Analogues nouveaux de prostaglandines

Country Status (9)

Country Link
US (20) US4055602A (fr)
JP (1) JPS5289649A (fr)
AU (1) AU502587B2 (fr)
BE (1) BE850204A (fr)
CH (1) CH627725A5 (fr)
DE (1) DE2659215A1 (fr)
FR (1) FR2337712A1 (fr)
NL (1) NL7700117A (fr)
ZA (1) ZA767465B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183870A (en) * 1974-01-26 1980-01-15 May & Baker Limited Cyclopentane derivatives
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4208538A (en) * 1976-01-08 1980-06-17 The Upjohn Company 2-Decarboxy-2-hydroxymethyl-3,7-inter-m-phenylene-ω-phenyl-PGF2 compounds
US4638100A (en) * 1976-01-08 1987-01-20 The Upjohn Company Aromatic or inter-oxa 2-decarboxy-2-hydroxymethyl-PGFα compounds
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US20030060878A1 (en) 2001-08-31 2003-03-27 Shadduck John H. Intraocular lens system and method for power adjustment
US8048155B2 (en) 2002-02-02 2011-11-01 Powervision, Inc. Intraocular implant devices
US6935743B2 (en) 2002-02-06 2005-08-30 John H. Shadduck Adaptive optic lens and method of making
US8328869B2 (en) 2002-12-12 2012-12-11 Powervision, Inc. Accommodating intraocular lenses and methods of use
US8361145B2 (en) 2002-12-12 2013-01-29 Powervision, Inc. Accommodating intraocular lens system having circumferential haptic support and method
US7637947B2 (en) 2002-12-12 2009-12-29 Powervision, Inc. Accommodating intraocular lens system having spherical aberration compensation and method
US7217288B2 (en) 2002-12-12 2007-05-15 Powervision, Inc. Accommodating intraocular lens having peripherally actuated deflectable surface and method
US10835373B2 (en) 2002-12-12 2020-11-17 Alcon Inc. Accommodating intraocular lenses and methods of use
US7306580B2 (en) * 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
CN1984839A (zh) 2004-03-24 2007-06-20 H.C.施塔克公司 形成具有可控和新型微观结构的α和β钽薄膜的方法
US20060292324A1 (en) * 2004-03-26 2006-12-28 Robert Roberts Uniaxially and biaxially-oriented polytetrafluoroethylene structures
US7906552B2 (en) * 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US9872763B2 (en) 2004-10-22 2018-01-23 Powervision, Inc. Accommodating intraocular lenses
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (fr) 2009-03-04 2010-09-10 Allergan, Inc. Solution ophtalmique améliorée à base de bimatoprost
EP2112932B1 (fr) 2007-02-21 2014-12-17 PowerVision, Inc. Matériaux polymères appropriés pour des dispositifs ophtalmiques et procédés de fabrication
US8968396B2 (en) 2007-07-23 2015-03-03 Powervision, Inc. Intraocular lens delivery systems and methods of use
CA2693906C (fr) 2007-07-23 2015-10-06 Powervision, Inc. Modification de puissance de lentille post-implant
US8314927B2 (en) * 2007-07-23 2012-11-20 Powervision, Inc. Systems and methods for testing intraocular lenses
WO2009015226A2 (fr) 2007-07-23 2009-01-29 Powervision, Inc. Accommodation de lentilles intraoculaires et procédés d'utilisation
US8956408B2 (en) 2007-07-23 2015-02-17 Powervision, Inc. Lens delivery system
US8668734B2 (en) 2010-07-09 2014-03-11 Powervision, Inc. Intraocular lens delivery devices and methods of use
US10299913B2 (en) 2009-01-09 2019-05-28 Powervision, Inc. Accommodating intraocular lenses and methods of use
ES2824842T3 (es) 2009-07-13 2021-05-13 Patheon Api Services Inc Síntesis de prostanoides
US8447086B2 (en) * 2009-08-31 2013-05-21 Powervision, Inc. Lens capsule size estimation
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2011106435A2 (fr) 2010-02-23 2011-09-01 Powervision, Inc. Fluide pour recevoir des lentilles intraoculaires
ES2875049T3 (es) 2011-03-24 2021-11-08 Alcon Inc Sistemas de carga de lentes intraoculares y métodos de uso
US10433949B2 (en) 2011-11-08 2019-10-08 Powervision, Inc. Accommodating intraocular lenses
WO2014145562A1 (fr) 2013-03-15 2014-09-18 Powervision, Inc. Dispositifs de stockage et de chargement de lentille intra-oculaire et procédés d'utilisation associés
US10100028B2 (en) 2013-09-30 2018-10-16 Patheon Api Services Inc. Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
AU2016349532B2 (en) 2015-11-06 2021-08-26 Alcon Inc. Accommodating intraocular lenses and methods of manufacturing
CN114760959A (zh) 2019-10-04 2022-07-15 爱尔康公司 可调节眼内晶状体和术后调节眼内晶状体的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959346A (en) * 1969-03-14 1976-05-25 The Upjohn Company Racemic prostaglandins of the 2-series and analogs thereof
DE2317019A1 (de) * 1972-04-27 1973-11-08 Upjohn Co Neue 4,5-didehydro-prostaglandine
US3914282A (en) * 1973-01-16 1975-10-21 Upjohn Co Prostaglandin E{HD 1{B , F{HD 1{B , and A{HD 1 {B analogs
US3962293A (en) * 1973-07-20 1976-06-08 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin F1
US3932463A (en) * 1974-06-03 1976-01-13 American Cyanamid Company 11-Deoxy-13-dihydro-prostaglandin-9-ketals

Also Published As

Publication number Publication date
US4127733A (en) 1978-11-28
FR2337712A1 (fr) 1977-08-05
US4108902A (en) 1978-08-22
CH627725A5 (de) 1982-01-29
US4107216A (en) 1978-08-15
NL7700117A (nl) 1977-07-12
JPS5289649A (en) 1977-07-27
US4108900A (en) 1978-08-22
US4108901A (en) 1978-08-22
US4111995A (en) 1978-09-05
US4110383A (en) 1978-08-29
US4107213A (en) 1978-08-15
US4107215A (en) 1978-08-15
US4113778A (en) 1978-09-12
US4107212A (en) 1978-08-15
BE850204A (fr) 1977-07-07
US4055602A (en) 1977-10-25
US4107214A (en) 1978-08-15
US4110381A (en) 1978-08-29
US4115454A (en) 1978-09-19
US4111996A (en) 1978-09-05
DE2659215A1 (de) 1977-07-21
US4110382A (en) 1978-08-29
AU502587B2 (en) 1979-08-02
US4110384A (en) 1978-08-29
US4108903A (en) 1978-08-22
ZA767465B (en) 1977-11-30
AU2077176A (en) 1978-06-29
US4107211A (en) 1978-08-15

Similar Documents

Publication Publication Date Title
FR2337712B1 (fr)
CH637799GA3 (fr)
DE2603057C2 (fr)
CS187793B1 (fr)
JPS52163584U (fr)
JPS5334889U (fr)
CH601079A5 (fr)
DD125665A1 (fr)
CH597986A5 (fr)
CH607273A5 (fr)
CH608969A5 (fr)
CH604235B5 (fr)
CH598547A5 (fr)
CH609290A5 (fr)
CH607242A5 (fr)
CH611976A5 (fr)
CH612271A5 (fr)
CH612475A5 (fr)
CH613145A5 (fr)
CH614003A5 (fr)
CH614357A5 (fr)
CH619340GA3 (fr)
CH606596A5 (fr)
DD123834A1 (fr)
CH599484A5 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse